Cargando…

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

BACKGROUND: Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wardlaw, Joanna M, Murray, Veronica, Berge, Eivind, del Zoppo, Gregory, Sandercock, Peter, Lindley, Richard L, Cohen, Geoff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Publishing Group 2012
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386494/ https://www.ncbi.nlm.nih.gov/pubmed/22632907 http://dx.doi.org/10.1016/S0140-6736(12)60738-7

Ejemplares similares

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited
por: Sandercock, Peter, et al.
Publicado: (2011)

The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
por: Sandercock, Peter, et al.
Publicado: (2008)

Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke
por: Wu, Simiao, et al.
Publicado: (2020)

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
por: Emberson, Jonathan, et al.
Publicado: (2014)

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
por: You, Shoujiang, et al.
Publicado: (2018)

Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
por: Wang, Xia, et al.
Publicado: (2018)

A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Observer reliability of CT angiography in the assessment of acute ischaemic stroke: data from the Third International Stroke Trial
por: Mair, Grant, et al.
Publicado: (2014)

Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function
por: Vogelgesang, Antje, et al.
Publicado: (2017)

Factors influencing the use of different methods of consent in a randomized acute stroke trial: The Third International Stroke Trial (IST-3)
por: Lindley, Richard I, et al.
Publicado: (2021)

Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
por: Dong, Yi, et al.
Publicado: (2016)

Feasibility and diagnostic accuracy of using brain attenuation changes on CT to estimate time of ischemic stroke onset
por: Mair, Grant, et al.
Publicado: (2020)

Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis
por: Guo, Yijia, et al.
Publicado: (2018)

Effect of X-Ray Attenuation of Arterial Obstructions on Intravenous Thrombolysis and Outcome after Ischemic Stroke
por: Mair, Grant, et al.
Publicado: (2015)

Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial
por: Muir, Keith W, et al.
Publicado: (2017)

Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials
por: Whiteley, William N, et al.
Publicado: (2013)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Local Cerebral Recombinant Tissue Plasminogen Activator Concentrations During Acute Stroke
por: Essig, Fabian, et al.
Publicado: (2021)

Normal Appearing Ischaemic Brain Tissue on CT and Outcome After Intravenous Alteplase
por: Mair, Grant, et al.
Publicado: (2022)

Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives
por: Zhao, Songfeng, et al.
Publicado: (2022)

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Publicado: (2012)

Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA
por: Joo, Heesoo, et al.
Publicado: (2016)

Acute symptomatic hypoglycaemia mimicking ischaemic stroke on imaging: a systemic review
por: Yong, Ai Wain, et al.
Publicado: (2012)

Baseline brain imaging signs in patients with ischaemic stroke by the presence of atrial fibrillation: the ENCHANTED trial
por: Wang, Xia, et al.
Publicado: (2023)

Prevalence of dementia in ischaemic or mixed stroke populations: systematic review and meta-analysis
por: Craig, Louise, et al.
Publicado: (2022)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
por: Gainey, Jordan, et al.
Publicado: (2018)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
por: Liu, Yonge, et al.
Publicado: (2020)

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
por: Mair, Grant, et al.
Publicado: (2016)

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
por: Kunjukunju, Nancy, et al.
Publicado: (2011)

ISCHAEMIC STROKE, PREVENTABLE WITH TISSUE ADHESIVE
por: Bothma, Pieter, et al.
Publicado: (2023)

Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers
por: Imbarrato, Gregory, et al.
Publicado: (2018)

It is safe to use transdermal glyceryl trinitrate to lower blood pressure in patients with acute ischaemic stroke with carotid stenosis
por: Appleton, Jason P, et al.
Publicado: (2019)

Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
por: Jung, Kee-Taig, et al.
Publicado: (2010)

Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
por: Tseng, Yi-Ju, et al.
Publicado: (2020)

Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
por: Huang, Yuyou, et al.
Publicado: (2023)

Physical and brain frailty in ischaemic stroke or TIA: Shared occurrence and outcomes. A cohort study
por: Taylor-Rowan, Martin, et al.
Publicado: (2023)

Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
por: Raczyńska, Dorota, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5vnpu6i6ug6808ledj5cjoj5v9